Ciprofloxacin-associated Peripheral Neuropathy in a Child: A Case Report and Review of the Literature

Morley, Carla; Almeida, Carla Carvalho de; Moloney, Susan; Grimwood, Keith

doi:10.1097/inf.0000000000003373

Cited by 5 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many cases of FQs-associated peripheral nervous system toxicity have been reported 20 21 including in children. 22 Some nested case–control studies determined that the risk of peripheral neuropathy is enhanced in current users of FQs. 23 24 In addition, a pharmacovigilance analysis of cases reported to FAERS until 2012 determined that systemic administration of FQs potentially was associated with peripheral neuropathy, nerve damage including Guillain-Barre syndrome.…”

Section: Peripheral Neuropathymentioning

confidence: 99%

Overview of Tendinopathy, Peripheral Neuropathy, Aortic Aneurysm, and Hypoglycemia Caused by Fluoroquinolones

Balasubramanian,

Maideen,

Narayanaswamy

2024

Ibnosina Journal of Medicine and Biomedical Sciences

View full text Add to dashboard Cite

Background Fluoroquinolones (FQs) are widely used in the management of several bacterial infections including urinary tract infections (UTIs), upper respiratory tract infections (URTIs), lower respiratory tract infections (LRTIs), skin and soft tissue, gastrointestinal tract infections (GITIs), and many other infections. Objective This review article focuses on some serious side effects notified by United States Food and Drug Administration (US FDA) in different warning statements. Methods The literature was searched, in databases such as Medline/PubMed/PMC, Google Scholar, Science Direct, Ebsco, Scopus, Web of science, Embase, and reference lists to identify publications relevant to the serious side effects associated with the use of FQs. Results Several epidemiological studies and meta-analyses have documented the occurrence of serious side effects of FQs including tendinopathy, peripheral neuropathy, aortic aneurysm/dissection, hypoglycemia, QT prolongation, retinal detachment, and worsening of myasthenia gravis. Conclusion The clinicians should be aware of serious side effects of FQs. The US FDA and European Medicines Agency recommend against the use of FQs as first-line therapies to treat infections such as acute sinusitis, acute bronchitis, and uncomplicated UTIs, as the risks outweigh the benefits. The risk of incidence of serious side effects of FQs is higher among patients with advanced age, renal insufficiency, and certain concomitant medications. To avoid occurrence of any serious side effects of FQs, the clinicians should prefer non-FQ antibacterial drugs to manage uncomplicated UTIs, respiratory tract infections, and other infections for which alternatives available.

show abstract